Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Abstract: Examples of the present disclosure relate to a device, method, and system for integrating a projection mode of a user mobile device with a terrestrial tuner. In an example, the system may be a vehicle including a head unit and a vehicle projection stack to operate in the head unit. The system may also include a terrestrial tuner communicatively coupled to the vehicle projection stack to receive a terrestrial signal from a terrestrial source. The system may also include an audio driver to provide an audio signal to a vehicle interior where the audio signal is from at least one of the terrestrial signal and an internet signal received at the vehicle projection stack from a user mobile device located inside the vehicle interior.

Abstract: In various examples, network conditions associated with a video stream are observed over time to determine a virtual scaling factor that may be applied to the images of one or more frames of the video stream to generate scaled images that may be appended with a padding region that maintains the original resolution of the video and/or video stream such that a receiving device may crop the padding region from the received video stream during the decoding process without restarting or including additional intra-coded frames.

Abstract: Examples of the present disclosure relate to a device, method, and system for integrating a projection mode of a user mobile device with a terrestrial tuner. In an example, the system may be a vehicle including a head unit and a vehicle projection stack to operate in the head unit. The system may also include a terrestrial tuner communicatively coupled to the vehicle projection stack to receive a terrestrial audio signal from a terrestrial source. The system may also include an audio driver to provide an audio signal to a vehicle interior where the audio signal is from at least one of the terrestrial audio signal and an internet audio signal received at the vehicle projection stack from a user mobile device located inside the vehicle interior.

Abstract: Examples of the present disclosure relate to a device, method, and system for integrating a projection mode of a user mobile device with a terrestrial tuner. In an example, the system may be a vehicle including a head unit and a vehicle projection stack to operate in the head unit. The system may also include a terrestrial tuner communicatively coupled to the vehicle projection stack to receive a terrestrial audio signal from a terrestrial source. The system may also include an audio driver to provide an audio signal to a vehicle interior where the audio signal is from at least one of the terrestrial audio signal and an internet audio signal received at the vehicle projection stack from a user mobile device located inside the vehicle interior.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Abstract: A process for providing a corrosion resistant coating on uncoated ferrous components, involving mechanical plating, using as a coating medium a zinc metal-containing powder, such as zinc or zinc alloy powder, or a powder mixture of zinc or zinc alloy and at least one other metal, so as to build up a firmly adherent coating of the coating medium over exposed surfaces of the components, heating the components with the firmly adherent coating to produce solid-solid diffusion to form an Fe/Zn intermetallic over the surfaces, at least in a base layer of the coating built up by the plating, and cooling the components.

Abstract: The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Abstract: The present invention encompasses compounds of the formula (I): wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Abstract: The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Abstract: Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.

Abstract: A process for providing a corrosion resistant coating on uncoated ferrous components, involving mechanical plating, using as a coating medium a zinc metal-containing powder, such as zinc or zinc alloy powder, or a powder mixture of zinc or zinc alloy and at least one other metal, so as to build up a firmly adherent coating of the coating medium over exposed surfaces of the components, heating the components with the firmly adherent coating to produce solid-solid diffusion to form an Fe/Zn intermetallic over the surfaces, at least in a base layer of the coating built up by the plating, and cooling the components

Abstract: Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1, X and G are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).

Abstract: Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.